COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression
COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression
复制标题
DOI：
10.1007/s11547-020-01200-3
复制
发表时间：
2020-05-01
影响因子：
8.9
通讯作者：
Maroldi, Roberto
中科院分区：
文献类型：
--
作者：
Borghesi, Andrea;Maroldi, Roberto
严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）是最近从人类身上分离到的一种新病毒。SARS-CoV-2被发现是2019年12月中国发生的与严重呼吸道疾病相关的聚集性肺炎病例的病原体。这种新型肺部感染，正式名称为2019冠状病毒病（COVID-19），已在中国及其他地区迅速蔓延。2020年3月8日，意大利感染SARS-CoV-2的人数为7375人，住院率为48%。目前，胸部ct成像被认为是早期发现肺部异常、定量评估COVID-19肺炎严重程度和进展的最有效方法。虽然胸部x线（CXR）被认为对疾病早期肺部受累的检测不敏感，但我们认为，在当前的急诊环境中，CXR可以作为一种有用的诊断工具，用于监测感染患者肺部异常的快速进展，特别是在重症监护病房。在这篇简短的交流中，我们介绍了我们的实验性CXR评分系统，我们正在将其应用于COVID-19肺炎住院患者，以量化和监测这种新型传染病的严重程度和进展。我们还介绍了我们对100名最终结果（康复或死亡）可用的住院SARS-CoV-2感染患者样本的初步验证研究结果。
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new virus recently isolated from humans. SARS-CoV-2 was discovered to be the pathogen responsible for a cluster of pneumonia cases associated with severe respiratory disease that occurred in December 2019 in China. This novel pulmonary infection, formally called Coronavirus Disease 2019 (COVID-19), has spread rapidly in China and beyond. On 8 March 2020, the number of Italians with SARS-CoV-2 infection was 7375 with a 48% hospitalization rate. At present, chest-computed tomography imaging is considered the most effective method for the detection of lung abnormalities in early-stage disease and quantitative assessment of severity and progression of COVID-19 pneumonia. Although chest X-ray (CXR) is considered not sensitive for the detection of pulmonary involvement in the early stage of the disease, we believe that, in the current emergency setting, CXR can be a useful diagnostic tool for monitoring the rapid progression of lung abnormalities in infected patients, particularly in intensive care units. In this short communication, we present our experimental CXR scoring system that we are applying to hospitalized patients with COVID-19 pneumonia to quantify and monitor the severity and progression of this new infectious disease. We also present the results of our preliminary validation study on a sample of 100 hospitalized patients with SARS-CoV-2 infection for whom the final outcome (recovery or death) was available.